As 2026 begins, the global hepatology community is closely monitoring a wave of breakthrough data from Phase II and III trials that aim to permanently correct the ATP7B genetic mutation. Regulatory authorities in the European Union and the United States have recently signaled a willingness to accept biomarker-driven endpoints, such as long-term reduction in non-ceruloplasmin bound copper, to...

The Hepatitis B Treatment Market is experiencing a significant transformation driven by the introduction of innovative therapies and heightened awareness about the disease. Current estimates place the Hepatitis B Treatment Market Size at approximately USD 4.28 billion, with projections forecasting a remarkable increase to USD 10.28 billion by 2035. This growth is underpinned by a compound...